TOPICAL CLOTRIMAZOLE 1% (CANDID) IN THE MANAGEMENT OF ACUTE PSEUDOMEMBRANOUS ORAL CANDIDIASIS IN NEONATES: CLINICAL EVIDENCE AND A PROSPECTIVE EVALUATION FRAMEWORK
Keywords:
neonatal oral candidiasis; pseudomembranous candidiasis; clotrimazole; Candid 1%; oral thrush; topical antifungal therapy; newborn safety; clinical effectiveness.Abstract
Acute pseudomembranous oral candidiasis is a frequent manifestation of mucosal Candida infection during early infancy, but neonatal-specific evidence for topical clotrimazole 1% solution, marketed in some settings as Candid, is limited. This article critically evaluates the clinical evidence relevant to its use and develops an outcome-oriented framework for prospective assessment in newborns. A targeted narrative synthesis was undertaken using neonatal case-series evidence, pediatric antifungal trials, contemporary clinical guidance, prescribing information and pharmacological safety assessments available through 14 November 2026. The most directly applicable study, a nonrandomized neonatal series, identified oral candidosis in 20 of 650 neonatal intensive-care admissions; 19 infants had a pseudomembranous phenotype. All 20 affected newborns received topical clotrimazole 1%, and visible lesions resolved within 2–6 days (median, 4 days); 12 infants were followed for three months without a documented recurrence. These observations are clinically encouraging but cannot establish comparative efficacy, because the treated group lacked an active-treatment control and the sample was small. Randomized studies of miconazole, nystatin and fluconazole in older infant populations support the importance of topical formulation and treatment adherence but do not directly quantify the effect of 1% clotrimazole in neonates. Differences in regional guidance, formulation excipients and neonatal vulnerability further limit extrapolation. A structured assessment of lesion clearance, feeding tolerance, recurrence, adverse events and product-specific exposure is proposed. Controlled neonatal studies with ethical oversight and locally authorized oral-mucosal formulations are required before definite conclusions regarding superiority or routine use can be drawn.
References
1.Gupta P, Faridi MMA, Rawat S, Sharma P. Clinical profile and risk factors for oral candidosis in sick newborns. Indian Pediatr. 1996;33(4):299–303. PMID: 8772904. https://pubmed.ncbi.nlm.nih.gov/8772904/
2.Ministry of Health of the Russian Federation. Neonatal Candidiasis: Clinical Recommendations. 2025; document ID 944_1. https://bazanpa.ru/minzdrav-rossii-klinicheskie-rekomendatsii-ot01012025-h6865185/
3.Glenmark Pharmaceuticals (Malaysia). Candid Mouth Paint 1% (clotrimazole): Registered Product Information. Revised August 9, 2021. https://quest3plus.bpfk.gov.my/front-end/attachment/4272/pharma/230937/V_54653_20210927_152709_D3.PDF
4.Candid 1% Solution for Local Use (Clotrimazole). Patient Information Leaflet, registration LP-No. (000553)-(RG-RU)-070222. https://stomatitu.net/media/docs/leaflet.pdf
5.Crowley PD, Gallagher HC. Clotrimazole as a pharmaceutical: past, present and future. J Appl Microbiol. 2014;117(3):611–617. doi:10.1111/jam.12554.
6.Hoppe JE; Antifungals Study Group. Treatment of oropharyngeal candidiasis in immunocompetent infants: a randomized multicenter study of miconazole gel vs nystatin suspension. Pediatr Infect Dis J. 1997;16(3):288–293. doi:10.1097/00006454-199703000-00007.
7.Hoppe JE, Hahn H. Randomized comparison of two nystatin oral gels with miconazole oral gel for treatment of oral thrush in infants. Infection. 1996;24(2):136–139. doi:10.1007/BF01713319.
8.Goins RA, Ascher D, Waecker N, Arnold J, Moorefield E. Comparison of fluconazole and nystatin oral suspensions for treatment of oral candidiasis in infants. Pediatr Infect Dis J. 2002;21(12):1165–1167. doi:10.1097/00006454-200212000-00017.
9.Pankhurst CL. Candidiasis (oropharyngeal). BMJ Clin Evid. 2012;2012:1304. PMID: 22348417. https://pmc.ncbi.nlm.nih.gov/articles/PMC4429411/
10.Médecins Sans Frontières. Oral and Oropharyngeal Candidiasis. MSF Medical Guidelines, 2025. https://medicalguidelines.msf.org/sites/default/files/2025-07/guideline-170-en.pdf
11.Canadian Paediatric Society. Antifungal Agents for Common Outpatient Paediatric Infections. Posted June 20, 2019; reaffirmed November 21, 2024. https://cps.ca/en/documents/position/antifungal-agents-common-infections
12.Te Whatu Ora Waikato. Candida Infections and Antifungal Treatment in the Newborn Unit. Guideline, version 02; February 23, 2024. https://healthshare.health.nz/file/2319/download?token=gQP3wXep
13.Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ933.
14.Dermitzaki N, Baltogianni M, Tsekoura E, Giapros V. Invasive Candida Infections in Neonatal Intensive Care Units: Risk Factors and New Insights in Prevention. Pathogens. 2024;13(8):660. doi:10.3390/pathogens13080660.
15.European Medicines Agency. Propylene Glycol Used as an Excipient: Report Published in Support of Questions and Answers on Propylene Glycol Used as an Excipient in Medicinal Products for Human Use. 2017. https://www.ema.europa.eu/en/documents/report/propylene-glycol-used-excipient-report-published-support-questions-and-answers-propylene-glycol-used-excipient-medicinal-products-human-use_en.pdf
16.National Institutes of Health. Candida Infections: Guidelines for Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. Updated December 22, 2025. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/candida-infections
17.Nurdiana, Naorungroj S, Sappayatosok K, Lomlim L, Pahumunto N. Efficacy of botanical antifungal and conventional antifungal in the treatment of oral candidiasis: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1635482. doi:10.3389/fphar.2025.1635482.
18.Médecins Sans Frontières. Miconazole Oral Gel: Essential Drugs Guidance. MSF Medical Guidelines. https://medicalguidelines.msf.org/en/viewport/EssDr/english/miconazole-oral-gel-16684167.html
